Application of TAGLN gene expression inhibitor in preparation of medicine for treating ovarian cancer

• Main Authors: GAO QINGLEI, WEI XIAO, JIA YIJUAN, YANG ZONGYUAN, MA DING
• Format: Patent
• Language: Chinese; English
• Published: 04.12.2018
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention belongs to the field of biomedicine and particularly relates to an application of a TAGLN gene expression inhibitor in the preparation of a medicine for treating ovarian cancer. The applicant studies the influence of different matrix hardness values on the malignant biological behavior of ovarian cancer cells from the perspective of biomechanics. Through an expressing spectrum chip,the selected gene TAGLN as a mechanically sensitive gene plays an important role in the malignant progression of ovarian cancer. Treatment is realized through down-regulation of expression of a targeted TAGLN gene. The in-vitro and in-vivo experiments prove that the TAGLN gene expression inhibitor can significantly inhibit the malignant biological behavior of ovarian cancer cells. The TAGLN gene expression inhibitor has a clinical application value for ovarian cancer. 本发明属于生物医学领域，具体涉及到TAGLN基因表达抑制剂在制备治疗卵巢癌药物中的应用，申请人从生物力学的角度，研究不同基质硬度对卵巢癌细胞恶性生物学行为的影响，通过表达谱芯片，筛选出的基因TAGLN作为个力学敏感性基因，在卵巢癌恶性进展中发挥了重要的作用。申请人通过靶向TAGLN基因进行的治疗，下调T